Our Products and Services

Oranoxis™ specializes in the development and manufacture of quantitative and qualitative immunoassays for drugs of abuse, food safety, environmental pollutants, and therapeutic drug monitoring. Our products meet high standards of accuracy, sensitivity, and precision due to our proprietary lateral flow platform technologies in addition to our strict quality management system. Please see our full product list, or click on the following product categories below for more specific details.

DOAicon ELISAicon reagenticon collectoricon

Oranoxis™ provides contract conjugation and nanoparticle technology services, and contract services for immunoassay development and manufacturing. We also provide consulting services for immunoassay R&D, quality control, and troubleshooting. Please see our full list of services for more information.

Please contact us for product and/or service inquiries, price quotations, and product distribution interests.

News and Events

March 2015
Oranoxis™ completes notification of all on-site drugs of abuse testing devices and receives new CE mark for Oral-AQ™, ToxWipe-Oral™, ToxWipe-Oral™ K2, and ToxStick K2™.

January 2015
Oranoxis™ launches ToxWipe-Oral™ K2 and ToxStick K2™ for on-site drugs of abuse testing of K2/synthetic cannabinoids. ToxWipe-Oral™ K2 is one of the first rapid test devices on the market capable of detecting K2/synthetic cannabinoids in oral fluid, and ToxStick K2™ detects major K2/synthetic cannabinoids in urine with high sensitivity.

August 2014
Oranoxis™ introduces a new product line, ToxWipe-Oral™, for on-site drugs of abuse testing. ToxWipe-Oral™ is designed to enhance convenience and ease of use for roadside and on-site preliminary testing, and allows for a more rapid sample collection by requiring a smaller volume of oral fluid.

April 2012
Oranoxis™ successfully receives ISO 13485:2003 certification by NSF International.

September 2010
National Institutes of Health (NIH) and National Cancer Institute (NCI) award Oranoxis™ with a grant for a contract project on the development of a rapid immunoassay for chemotherapeutic drug monitoring.

December 2009
Oranoxis™ presents immunoassay R&D report at a conference held at Harvard Medical School.

August 2009
Oranoxis™ launches On-site Oral-AQ, an oral fluid multi-drug test that has a removable sample retention cup for storing saliva samples for confirmation testing.

Quality Commitment

Oranoxis™ is committed to providing high quality products and services. Our quality management system enforces strict quality control and quality assurance practices to ensure the exceptional quality of our products and services.

Oranoxis™ is a FDA registered medical device manufacturer and is ISO 13485:2003 certified by NSF International.

We comply with current Good Manufacturing Practices (cGMP)/Quality System Regulation (QSR). All of our products are Made in the USA and CE marked for proof of quality comformance with European IVD Directive 98/79/EC.

Additionally, our oral fluid sample collection device is composed of medical grade materials that are "Generally Recognized As Safe" (GRAS) by the Food and Drug Administration (FDA).